Subscribe to our press releases
Share
Correction of press release December 18th
ChromoGenics AB (publ) corrects the date for the last trading day including the right to participate in a rights issue is 22 January 2019.
The first trading day for the ChromoGenics share, excluding the right to participate in the rights issue, is therefore January 23, 2019.
Correct indicative timetable
| 17 January 2019 | Extraordinary general meeting to approve the board of directors’ resolution on the Rights Issue |
| 22 January 2019 | Last day of trade in the ChromoGenics share including the right to participate in the Rights Issue |
| 23 January 2019 | First day of trade in the ChromoGenics share excluding the right to participate in the Rights Issue, the ex-date |
| 24 January 2019 | Record date for the right to participate in the Rights Issue |
| 28 January – 13 February 2019 | Trade in subscription rights |
| 28 January – 15 February 2019 | Subscription period |
| About 18 February 2019 | Announcement of preliminary outcome of the Rights Issue |
Contact:
Jerker Lundgren, CEO
Susanne Andersson, CFO and Head of Communications
Tel: +46 (0)18 430 0430
E-mail: info@chromogenics.com
Certified Adviser: G&W Fondkommission
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
About ChromoGenics
ChromoGenics offers dynamic glass with controllable heat- and light transmission. The company’s unique technology ConverLight® provides sustainable solar control for increased indoor comfort and energy efficiency. ConverLight® also contributes to Green Building certifications. In 2016 the company started commercial sales to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala, Sweden, and the technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.
ChromoGenics
Subscribe
Co-financed by
